InMed Pharmaceuticals (MWG) Income Statement
InMed Pharmaceuticals Income Statement
Last quarter (Q4 2026), InMed Pharmaceuticals's total revenue was $2.06B, an increase of 115691.64% from the same quarter last year. In Q4, InMed Pharmaceuticals's net income was $-5.08M. See InMed Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Jun 26 | Jun 25 | Jun 24 | Jun 23 | Jun 22 |
|---|---|---|---|---|---|
| $ 3.18B | $ 4.94M | $ 4.60M | $ 4.14M | $ 1.09M | |
| $ 709.84M | $ 1.71M | $ 1.10M | $ 1.40M | $ 543.55K | |
| $ 9.19M | $ 9.62M | $ 9.24M | $ 9.78M | $ 14.34M | |
| Depreciation and Amortization | $ 708.36K | $ 534.73K | $ 604.52K | $ 596.00K | $ 511.79K |
| $ -9.19M | $ -7.26M | $ -7.06M | $ -7.34M | $ -18.09M | |
| $ -9.90M | $ -7.92M | $ -8.13M | $ -8.38M | $ -13.79M | |
| $ -1.48M | $ -244.14K | $ 465.98K | $ 444.26K | $ -4.81M | |
| $ -11.37M | $ -8.16M | $ -7.67M | $ -7.93M | $ -18.60M | |
| $ -12.56M | $ -8.16M | $ -7.68M | $ -7.95M | $ -18.60M | |
| Per Share Metrics | |||||
| Basic EPS | $ -3.12 | $ -8.36 | $ -20.14 | $ -64.92 | $ -16582.00 |
| Diluted EPS | $ -3.12 | $ -8.36 | $ -20.14 | $ -64.92 | $ -16582.00 |
| Weighted Average Shares Outstanding | 4.16M | 975.99K | 381.05K | 122.42K | 1.12K |
| Weighted Average Shares Outstanding (Diluted) | 4.16M | 975.99K | 381.05K | 122.42K | 1.12K |
Currency in CAD
